Literature DB >> 2492020

Effects of apolipoproteins A-IV and A-I on the uptake of phospholipid liposomes by hepatocytes.

C L Bisgaier1, M V Siebenkas, K J Williams.   

Abstract

We examined the effects of apolipoproteins A-IV and A-I on the catabolism of whole particles by hepatoma G2 cells and cultured primary hepatocytes. For this type of experiment, high density lipoprotein is unsuitable, because all of its lipid and protein components independently dissociate and exchange and hence poorly trace whole particle catabolism. We therefore used phosphatidylcholine liposomes with radioactive tracers entrapped within their aqueous cores. Apolipoproteins A-IV, A-I, or E added to liposomes became liposome-associated and produced no detectable release of encapsulated label. As a positive control, apolipoprotein E doubled the uptake of labeled liposomes by hepatoma cells, compared to apolipoprotein-free controls, and this increase could be blocked by the addition of excess unlabeled low density lipoprotein. Degradation of labeled liposomes by hepatoma cells was increased 6-fold by the addition of apolipoprotein E. In contrast, neither apolipoprotein A-IV nor A-I increased cellular uptake or degradation of the particles. Similar results were obtained with primary hepatocytes. In studies using apolipoprotein combinations, apolipoproteins A-IV and A-I were each able to displace apolipoprotein E from liposomes and thereby reduce cellular uptake. Our data indicate that apolipoproteins A-IV and A-I do not facilitate uptake or degradation of whole particles by liver-derived cells in vitro. However, these apolipoproteins may modulate receptor-mediated uptake of particles by reducing the amount of particle-bound apolipoprotein E.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2492020

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

Review 1.  Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups.

Authors:  S M Moghimi; A C Hunter
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

Review 2.  Treating metastatic cancer with nanotechnology.

Authors:  Avi Schroeder; Daniel A Heller; Monte M Winslow; James E Dahlman; George W Pratt; Robert Langer; Tyler Jacks; Daniel G Anderson
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

3.  Delivery of siRNA to the mouse lung via a functionalized lipopolyamine.

Authors:  Kevin J Polach; Majed Matar; Jennifer Rice; Gregory Slobodkin; Jeff Sparks; Richard Congo; Angela Rea-Ramsey; Diane McClure; Elaine Brunhoeber; Monika Krampert; Andrea Schuster; Kerstin Jahn-Hofmann; Matthias John; Hans-Peter Vornlocher; Jason G Fewell; Khursheed Anwer; Anke Geick
Journal:  Mol Ther       Date:  2011-10-11       Impact factor: 11.454

4.  Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.

Authors:  Akin Akinc; William Querbes; Soma De; June Qin; Maria Frank-Kamenetsky; K Narayanannair Jayaprakash; Muthusamy Jayaraman; Kallanthottathil G Rajeev; William L Cantley; J Robert Dorkin; James S Butler; Liuliang Qin; Timothy Racie; Andrew Sprague; Eugenio Fava; Anja Zeigerer; Michael J Hope; Marino Zerial; Dinah W Y Sah; Kevin Fitzgerald; Mark A Tracy; Muthiah Manoharan; Victor Koteliansky; Antonin de Fougerolles; Martin A Maier
Journal:  Mol Ther       Date:  2010-05-11       Impact factor: 11.454

5.  Ionizable amphiphilic dendrimer-based nanomaterials with alkyl-chain-substituted amines for tunable siRNA delivery to the liver endothelium in vivo.

Authors:  Omar F Khan; Edmond W Zaia; Hao Yin; Roman L Bogorad; Jeisa M Pelet; Matthew J Webber; Iris Zhuang; James E Dahlman; Robert Langer; Daniel G Anderson
Journal:  Angew Chem Int Ed Engl       Date:  2014-10-29       Impact factor: 15.336

6.  Hepatic overexpression of bovine scavenger receptor type I in transgenic mice prevents diet-induced hyperbetalipoproteinemia.

Authors:  S Wölle; D P Via; L Chan; J A Cornicelli; C L Bisgaier
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

7.  Hepatic lipase may act as a ligand in the uptake of artificial chylomicron remnant-like particles by isolated rat hepatocytes.

Authors:  P Diard; M I Malewiak; D Lagrange; S Griglio
Journal:  Biochem J       Date:  1994-05-01       Impact factor: 3.857

8.  Intestinal expression of human apolipoprotein A-IV in transgenic mice fails to influence dietary lipid absorption or feeding behavior.

Authors:  K Aalto-Setälä; C L Bisgaier; A Ho; K A Kieft; M G Traber; H J Kayden; R Ramakrishnan; A Walsh; A D Essenburg; J L Breslow
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

Review 9.  MicroRNAs and drug resistance in prostate cancers.

Authors:  Feng Li; Ram I Mahato
Journal:  Mol Pharm       Date:  2014-04-29       Impact factor: 4.939

10.  Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro. A possible pathophysiologic explanation for familial combined hyperlipidemia.

Authors:  K J Williams; K A Petrie; R W Brocia; T L Swenson
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.